CD8A and graft versus host disease: In our AIM ACT trials we have confirmed that E+E cells are well tolerated with no induced graft-vs-host disease (GVHD) or other grade 3-4 adverse events while observing clinical activity and persistence of our infused antigen-specific CD8+ T cells (27).